Results 71 to 80 of about 21,834 (257)

Pseudoephedrine-induced Fixed Drug Eruption in a Scuba Diver With Recurrent Palmoplantar Exfoliation [PDF]

open access: yesJournal of Preventive Medicine and Public Health
This report presents a case of pseudoephedrine-induced non-pigmented bullous fixed drug eruption (NBFDE) manifesting as recurrent palmoplantar exfoliation in a scuba diver.
Pimpreeya Kajornchaikul   +2 more
doaj   +1 more source

Fixed Solar Eruption: A Case Report

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Fixed eruption is characterized by recurrent lesions at identical anatomical sites after exposure to a trigger. Although most cases are drug‐induced, ultraviolet (UV) radiation has also been reported as a causative factor. We report a case of fixed solar eruption diagnosed by histopathology and 308 nm excimer light phototesting.
Yukiko Tateno   +3 more
wiley   +1 more source

Bullous Fixed Drug Eruption Induced by Paracetamol: Report of a Pediatric Case

open access: yesCase Reports in Dermatology, 2009
Drug eruptions are among the most common adverse drug reactions, affecting approximately 3% of hospitalized patients. A fixed drug eruption (FDE) is a distinct drug-induced reaction pattern that characteristically recurs at the same skin or mucosal site.
Massimiliano Nino   +3 more
doaj   +1 more source

Bio‐Derived Carbon Nanoparticles: A Green Amendment for Alleviating Heavy Metals in Soil–Plant Systems

open access: yesLand Degradation &Development, EarlyView.
ABSTRACT Heavy metal (HM) contamination of soil–plant systems poses persistent ecological and health risks, driving interest in nanoparticle‐based remediation. Although conventional chemically synthesized nanoparticles (CSNPs) are effective, their energy‐intensive production and residual toxicity limit sustainable deployment.
Babar Hussain   +6 more
wiley   +1 more source

Histological patterns of cutaneous adverse drug reactions

open access: yesHU Revista, 2010
Cutaneous adverse drug reactions (ADR) are skin conditions due to a drug, regardless of the way of administration.  Knowledge about their frequency, clinical manifestations and histopathological patterns is essential for prevention and early diagnosis ...
Sonia Maria Neumann Cupolilo   +5 more
doaj  

Iododerma after Lugol use for pre-operative preparation of thyroidectomy

open access: yesRevista da Sociedade Portuguesa de Dermatologia e Venereologia, 2022
A 35-year-old man with hyperthyroidism reported the sudden occurrence of ulcerated and painful oral lesions, painful ulcerative-necrotic lesions on the face, trunk, upper and lower limbs and purpuric circinate lesions on the scalp, 6 days after starting ...
David Almeida   +6 more
doaj  

Fixed drug eruption

open access: yesCanadian Medical Association Journal, 2022
Chou, Yu-Ju, Chang, Hua-Ching
openaire   +2 more sources

532‐nm KTP Laser Treatment of Epidermal Growth Factor Receptor Inhibitor–Associated Paronychia: A Case Report

open access: yesLasers in Surgery and Medicine, EarlyView.
ABSTRACT Objectives Paronychia is a common and often painful cutaneous adverse event of epidermal growth factor receptor inhibitor therapy that can impair function and quality of life. We report the first known case of amivantamab‐associated paronychia successfully treated with 532‐nm potassium‐titanyl‐phosphate laser.
Emilee M. Dreifus   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy